400
Participants
Start Date
August 13, 2021
Primary Completion Date
November 30, 2025
Study Completion Date
December 31, 2025
Centhaquine
Centhaquine (LYFAQUIN™ or centhaquine citrate) is a novel, first-in-class, highly effective resuscitative agent for hypovolemic shock. Phase II results demonstrate highly significant efficacy in improving blood pressure (p\<0.0001), lactate levels (p=0.0012) and base-deficit (p\<0.0001). There was also improvement in reduction in use of vasopressors and reduced mortality. Similarly, results of phase III study confirmed the safety and efficacy of centhaquine as an adjuvant to standard of care for hypovolemic shock. Therefore, to assess safety of centhaquine in large population a phase IV study (post-authorization safety study) has been designed.
RECRUITING
Dayanand Medical College & Hospital (DMCH), Ludhiana
RECRUITING
Christian Medical College and Hospital (CMC), Ludhiana
RECRUITING
Sri Guru Ram Das University of Health Sciences (SGRDH), Amritsar
RECRUITING
Ganesh Shankar Vidyarthi Memorial Medical College (GSVM), Kanpur
RECRUITING
Janta Hospital, Varanasi
RECRUITING
Pushpanjali Hospital, Agra
RECRUITING
Maharani Laxmi Bai Medical College (MLBMC), Jhānsi
RECRUITING
Nirmal Hospital, Jhānsi
RECRUITING
Government Medical College, Kota
RECRUITING
Aman Hospital, Vadodara
RECRUITING
New Era Hospital, Nagpur
RECRUITING
Seven Star Hospital, Nagpur
RECRUITING
Meditrina Hospital, Nagpur
RECRUITING
All India Institute of Medical Sciences (AIIMS), Raipur
RECRUITING
ACSR Government Medical College and Hospital, Nellore
RECRUITING
KG Hospital, Coimbatore
RECRUITING
IPGMER & SSKM Hospital, Kolkata
Lead Sponsor
Pharmazz, Inc.
INDUSTRY